In a First, Scientists Say They’ve Partially Reversed a Cellular Aging Process in Humans – ScienceAlert
Posted: November 20, 2020 at 5:57 pm
Every time a cell inside your body replicates, a slither of your youth crumbles to dust. This occurs via the shortening oftelomeres, structures that 'cap' the tips of our chromosomes.
Now, scientists in Israel say they've been able to reverse this process and extend the length of telomeres in a small study involving 26 patients.
The participants sat in a hyperbaric oxygen chamber for five 90 minutes sessions per week over three months, and as a result, some of their cell's telomeres were extended by up to 20 percent.
It's an impressive claim - and something many other researchers have attempted in the past without success. But of course it's worth flagging that this is a small sample size, and the results will need to be replicated before we can get too excited.
However, the fact that hyperbaric oxygen therapy appears to affect telomere length is a compelling link worth investigating further.
Lead researcher Shair Efrati, a physician from the Faculty of Medicine and Sagol School of Neuroscience at Tel Aviv University, explained to ScienceAlert how the inspiration behind their experiment was somewhat out of this world.
"After the twin experiment done by NASA, where one of the twins was sent out to the outer space and the other stayed on Earth, demonstrated a significant difference in their telomere length we have realised that changes in the outside environment may affect the core cellular changes that happens along ageing," said Efrati.
Telomeres are repeating chunks of code that act as the DNA equivalent of the plastic or metal aglet capping the end of a shoelace.
They copy themselves along with the rest of the chromosomes whenever a cell divides. Yet with every replication, tiny fragments of code from the very tip of the sequence fail to make it into the new copy, leaving the freshly minted chromosome a touch shorter than its predecessor.
As anybody who has lost the cap of their shoelace knows, it doesn't take long for the shoelace to lose its integrity. Similarly, shorter telomeres put sequences further down the chromosome at higher risk of hazardous mutations.
These mutations coincide with changes that predispose us to a bunch of age-related conditions, not least of all diseases such as cancer.
That's not necessarily to say that we age because our telomeres shrink, but there is a connection between telomere length and health that researchers are keen to investigate further.
"Longer telomeres correlates with better cellular performance," Efriti explained.
There are plenty of ways to accelerate the erosion of our telomeres. Failing to get adequate sleepcould do it, as might chowing down on too much processed food, and maybe even having kids.
Slowing down the loss takes a bit more effort, but engaging in regular exercise and eating well are sound bets if you want your chromosomes to remain as long as possible.
A real achievement would be to flip our chromosomal hourglass completely and return lost sections of telomere. The fact that high-turnover tissues lining our gut do this naturally using an enzyme called telomerase has fuelled research over the years.
There have been plenty of milestones in attempts to achieve this task. Gene therapy in mice has shown it could one day be feasible in humans. More recently, stem cells from a supercentenarian woman had their telomeres completely reset outside of her body.
Some studies have found potential for tiny increases of maybe a few percent with provision ofnutritional supplementssuch asvitamin D.
But while there are plenty of hyped promises of reversing aging in living humans already on the market, the reality of science-backed therapies we can use to give us the telomeres of a 20-year-old has been underwhelming.
Which is why the latest study is attracting so much attention. Far from a measly two or three percent, this latest study found telomeres in white blood cells taken from 26 subjects had regained around a fifth of their lost length.
The key, it seems, is hyperbaric oxygen therapy (HBOT) the absorbing of pure oxygen while sitting in a pressurised chamber for extensive periods; in this case, five 90 minute sessions per week over three months.
HBOT has attracted controversy in the past for claims it could treat a range of conditions.It's usually the kind of therapy you'd give a diver who came up too fast from the ocean depths, or to kill off oxygen-sensitive microbes in a wound that just won't heal any other way.
But oxygen-rich environments are also behind a weird paradox, one where the body desperately stirs up a host of genetic and molecular changes that typically occur in a low oxygen one.
In this study, the researchers were able to show that the genetic changes provoked by the HBOT has extended telomeres, and also had a potentially positive effect on the health of the tissues themselves.
A slightly smaller sample of volunteers also showed a significant decrease in the number of senescentT cells, tissues that form a vital part of our immune system's targeted response against invaders.
Whether you'd sit in a small tank every day for a quarter of a year is a matter of preference, but future research could help make the whole process a touch more efficient, at least for some.
"Once we have demonstrated the reverse ageing effect on the study cohort using predefined HBOT protocol, further studies are needed in order to optimise the specific protocol per individual," Efrati told ScienceAlert.
In a press release from The Sagol Center for Hyperbaric Medicine and Research, Efrati says understanding telomere shortening is "considered the 'Holy Grail' of the biology of aging".
As significant as telomere shrinking seems to be, the failure of our biology as we age is no doubt a complicated matter involving far more than lost pieces of chromosomes.
Reactivation of telomerase is also a trick used by cancers to remain ahead of the growth-curve, making this holy grail a potentially poisoned chalice we need to understand better before drinking too heavily from.
Excitingly, research like this will help us develop a better picture of the aging process.
This research was published in Aging.
- Advarra Announces New Gene Therapy Ready Site Network - PRNewswire - January 23rd, 2021
- UK biotech Ixaka scores additional funding for cell and gene therapy research - PharmaTimes - January 23rd, 2021
- Neurogene and University of Edinburgh Announce Research Collaboration to Advance Next Generation Gene Therapies - Business Wire - January 23rd, 2021
- Cure Genetics Collaborates with Boehringer Ingelheim to Develop Novel AAV Vectors Enabling the Next-generation Liver-targeted Gene Therapy - BioSpace - January 23rd, 2021
- Cancer Gene Therapy Market Size Study with COVID-19 Impact 2020, Share, Industry Analysis, Growth, Segmentation and Forecast to 2026 KSU | The... - January 23rd, 2021
- Chinese scientists develop new gene therapy that can delay the aging process - National Post - January 23rd, 2021
- Gene therapy developed to delay ageing - The Financial Express - January 23rd, 2021
- Bone Therapeutics provides fourth quarter 2020 business update and 2021 outlook - GlobeNewswire - January 23rd, 2021
- How 2 scientific pioneers teamed up to run AskBio, Bayer's new gene therapy division - BioPharma Dive - January 22nd, 2021
- Neurogene in tie up with university to advance gene therapy technologies - BioPharma-Reporter.com - January 22nd, 2021
- Cell and Gene Therapy Consumables Market 2020 Key Manufacturers, Development Trends and Competitive Analysis 2026 KSU | The Sentinel Newspaper - KSU... - January 22nd, 2021
- New Research Grant Seeks to Clarify the Role Genes Play in Modulating Inflammation - NYU Langone Health - January 22nd, 2021
- Lilly Completes Acquisition of Prevail Therapeutics - BioSpace - January 22nd, 2021
- Cancer Gene Therapy Market : Future Prospects With Covid-19 Impact Analysis 2027 | Top Players- Adaptimmune, GlaxoSmithKline plc, bluebird bio, Inc -... - January 22nd, 2021
- Global Gene Therapy Market Worth $38.41 Million by 2025- Exclusive Report by Fior Markets - PharmiWeb.com - January 22nd, 2021
- Covance boosts Franklin to lead its cell and gene therapy unit - FierceBiotech - January 22nd, 2021
- Explore why Cancer Gene Therapy Market is thriving by 2025 with top key players like Genelux Corporation, Cell Genesys, Advantagene, GenVec,... - January 22nd, 2021
- The global transient protein expression market is expected to reach US$ 983.10 million by 2027 from US$ 660.00 million in 2019 - GlobeNewswire - January 22nd, 2021
- Regenerative Medicine Market Size Worth $23.57 Bn By 2027; High demand for 3D bioprinting of tissues and organs to better understand their mechanism... - January 22nd, 2021
- Cancer Gene Therapy Market Segmentation, Parameters, Prospects 2021 And Forecast Research Report To 2027 - The Courier - January 22nd, 2021
- Taysha Gene Therapies Receives Rare Pediatric Disease and Orphan Drug Designations for TSHA-105 for the Treatment of Epilepsy Caused by SLC13A5... - January 22nd, 2021
- The Global Cancer Gene Therapy Market is expected to grow by $ 2.96 bn during 2021-2025 progressing at a CAGR of 20% during the forecast period -... - January 22nd, 2021
- Gene Therapy Technologies Market Estimated to Experience a Hike in Growth by 2021 2026: Bluebird bio, Adaptimmune, GlaxoSmithKline - KSU | The... - January 22nd, 2021
- Unleashing the cancer-fighting gene TP53 in leukemia with a novel combination treatment - FierceBiotech - January 22nd, 2021
- Big Boom in Gene Therapy Market Detailed Analysis of Current and Future Industry Figures till 2028 |Novartis AG, Gilead Sciences, Inc., UniQure N.V.,... - January 22nd, 2021
- Gene therapy developed to delay ageing - The Financial Express BD - January 22nd, 2021
- Biogen and ViGeneron to Collaborate on Ophthalmic Gene Therapy Development - JD Supra - January 9th, 2021
- With decades in gene therapy under his belt, Ronald Crystal launches new venture with up to 18 candidates in the pipe - Endpoints News - January 9th, 2021
- GeneOne to supply plasmid DNA therapy worth $2 million to US - Korea Biomedical Review - January 9th, 2021
- Fujifilm triples down on viral vector manufacturing with new $40M Boston site - FiercePharma - January 9th, 2021
- REGENXBIO Announces Update on RGX-314 and Pivotal Program for the Treatment of Wet AMD and New Gene Therapy Program for the Treatment of Duchenne... - January 9th, 2021
- Gene therapy for tuberous sclerosis complex type 2 in a mouse model by delivery of AAV9 encoding a condensed form of tuberin - Science Advances - January 9th, 2021
- Chinese researchers discover new anti-aging gene therapy - The Star Online - January 9th, 2021
- Engineered stem cells that evade immune detection could boost cell therapy and I-O - FierceBiotech - January 9th, 2021
- article image Advances in gene therapy to help paralysis - Digital Journal - January 9th, 2021
- Oncternal Therapeutics and Karolinska Institutet Establish Collaboration for Research and Development of ROR1-targeting CAR-T and CAR-NK Cell... - January 9th, 2021
- AllStripes Announces Collaboration with Taysha Gene Therapies for SURF1-Associated Leigh Syndrome Program - Business Wire - January 9th, 2021
- Regenerative Medicine Market to Reach Valuation US$ 23.7 Bn by 2027 - GlobeNewswire - January 9th, 2021
- Global Cell and Gene Therapy Market Report 2020-2030: COVID-19 Impacts, Growth and Changes - GlobeNewswire - January 9th, 2021
- Mana joins the hectic fight against solid tumors with an 'off-the-shelf' candidate angling for an IND this year - Endpoints News - January 9th, 2021
- Dewpoint forges another big pharma partnership and a potential rivalry - BioPharma Dive - January 9th, 2021
- IsoPlexis scores big backer for personalized protein 'barcodes' as Perceptive jumps on board new funding round - Endpoints News - January 9th, 2021
- Global Soft Tissue Repair Market- Featuring 3M Co., Arthrex Inc., and Baxter International Inc. Among Others - Business Wire - January 9th, 2021
- Looking to solve the solid tumor puzzle box, Carisma aims to take 'CAR-M' groundbreaker into early-stage trial - Endpoints News - January 9th, 2021
- DiCE gets its 'library' card ready as it speeds development of DNA database-derived molecules with more investor cash - Endpoints News - January 9th, 2021
- Study: Too few with high blood pressure tested for hormone disorder - UPI News - December 30th, 2020
- These Families Raised Millions To Fund Treatment For Their Kids' Genetic Disorders. It Hasn't Happened. - KCUR - December 26th, 2020
- Taysha Gene Therapies Announces Queen's University's Receipt of Clinical Trial Application Approval from Health Canada for Phase 1/2 Clinical Trial of... - December 26th, 2020
- After years of potential, cell and gene therapy is ready for the pharmaceutical mainstream - PMLiVE - December 26th, 2020
- Regenerative Medicine in Pharma 2020 - Opportunities, Challenges, and Unmet Needs - GlobeNewswire - December 26th, 2020
- Gene Therapy for Rare Disease Market Prospects Pinpoint Higher Traction from Developed Nations during 2020-2026 | Coherent Market Insights | Kite... - December 26th, 2020
- Gene Therapy Market Regions, Type and Application, Futuristic Study - Factory Gate - December 26th, 2020
- News briefing: Merck buys into A2's T cell therapy platform; Small Soligenix reports PhIII fail in head and neck cancer - Endpoints News - December 26th, 2020
- Biopharma Money on the Move: December 16-22 - BioSpace - December 26th, 2020
- Ziopharm Oncology Announces Clearance of Taiwan's First IND of Non-viral CAR-T for the Treatment of Relapsed CD19+ Leukemias and Lymphomas -... - December 26th, 2020
- Ocugen Establishes Vaccine Scientific Advisory BoardLeading experts to evaluate the clinical and regulatory path to approval in the US market of... - December 26th, 2020
- Allogene Therapeutics Receives IND Clearance from the U.S. Food and Drug Administration for ALLO-715 in Combination with Nirogacestat in... - December 26th, 2020
- Gyroscope Therapeutics and the University of Pennsylvania Announce Research Agreement to Develop Gene Therapies for Serious Eye Diseases - Business... - December 19th, 2020
- Every Patient Treated With CRISPR Gene Therapy for Blood Diseases Continues to Thrive, More Than a Year On - Good News Network - December 19th, 2020
- The next generation of gene therapy for rare diseases forges ahead as developers weather hurdles - FierceBiotech - December 19th, 2020
- Atsena Therapeutics Raises $55 Million Series A Financing to Advance LCA1 Gene Therapy Clinical Program, Two Preclinical Assets, and Novel Capsid... - December 19th, 2020
- Repurposing a proven gene therapy approach to treat, prevent COVID-19 - Penn Today - December 19th, 2020
- Locanabio Raises $100 Million to Advance RNA-Targeted Gene Therapies - BioSpace - December 19th, 2020
- Technical Report on Gene Therapy in Oncology Market 2021 - LionLowdown - December 19th, 2020
- Biopharma Money on the Move: December 9-15 - BioSpace - December 19th, 2020
- Global Gene Expression Market Analysis and Forecasts - A $6.78 Billion Market by 2027 - PRNewswire - December 19th, 2020
- Though Promising, Gene Therapies Face Durability And Reimbursement Headwinds - Forbes - December 17th, 2020
- Lilly scores gene therapy programme in $1bn Prevail Therapeutics acquisition deal - PMLiVE - December 17th, 2020
- Gene Therapy in One Eye Improves Vision in Both Eyes - The Scientist - December 17th, 2020
- Gene Therapy Market Worth USD 35.67 Billion at 33.6% CAGR; Rising Prevalence of Spinal Muscular Atrophy to Augment Growth: Fortune Business Insights -... - December 17th, 2020
- Health Canada approves Zolgensma, the one-time gene therapy for pediatric patients with spinal muscular atrophy (SMA) - Canada NewsWire - December 17th, 2020
- Global Gene Therapy Market Report 2020-2030 Featuring Novartis, Bluebird Bio, Spark Therapeutics, Audentes Therapeutics, Voyager Therapeutics,... - December 17th, 2020
- Passage Bio Invests In Gene Therapy Manufacturing R&D Site - Contract Pharma - December 17th, 2020
- Experimental Therapy Injected in One Eye Unexpectedly Improves Vision in The Other - ScienceAlert - December 17th, 2020
- After leaving Wall Street to launch a gene therapy upstart, Rachel McMinn nabs $115M to drive her first candidate to the clinic - Endpoints News - December 17th, 2020
- They thought their gene therapy failed. Instead, it spawned a medical mystery - Endpoints News - December 17th, 2020
- Cell And Gene Therapy Market Trends, Growth, Size, Analysis and Forecast by 2024 with Top Players: JW CreaGene,Vericel,Tego Sciences,GC... - December 17th, 2020
- Single gene therapy injection surprisingly boosts vision in both eyes - New Atlas - December 17th, 2020
- Cell and Gene Therapy Global Market Report 2020-30: COVID-19 Growth and Change - GlobeNewswire - December 17th, 2020
- Cancer Gene Therapy Market Global Opportunities and Industry Share Expected Surpass $2082 Million b - PharmiWeb.com - December 17th, 2020